Literature DB >> 26567024

Pathogenesis of thyroid eye disease: review and update on molecular mechanisms.

Jwu Jin Khong1, Alan A McNab2, Peter R Ebeling3, Jamie E Craig4, Dinesh Selva5.   

Abstract

Orbital changes in thyroid orbitopathy (TO) result from de novo adipogenesis, hyaluronan synthesis, interstitial oedema and enlargement of extraocular muscles. Cellular immunity, with predominantly CD4+ T cells expressing Th1 cytokines, and overexpression of macrophage-derived cytokines, perpetuate orbital inflammation. Orbital fibroblasts appear to be the major effector cells. Orbital fibroblasts express both thyrotropin receptor (TSHR) and insulin-like growth factor-1 receptor (IGF-1R) at higher levels than normal fibroblasts. TSHR expression increases in adipogenesis; TSHR agonism enhances hyaluronan production. IGF-1R stimulation leads to adipogenesis, hyaluronan synthesis and production of the chemokines, interleukin (IL)-16 and Regulated on Activation, Normal T Cell Expression and Secreted, which facilitate lymphocyte trafficking into the orbit. Immune activation uses a specific CD40:CD154 molecular bridge to activate orbital fibroblasts, which secrete pro-inflammatory cytokines including IL-1β, IL-1α, IL-6, IL-8, macrophage chemoattractant protein-1 and transforming growth factor-β, to perpetuate orbital inflammation. Molecular pathways including adenylyl cyclase/cyclic adenosine monophosphate, phophoinositide 3 kinase/AKT/mammalian target of rapamycin, mitogen-activated protein kinase are involved in TO. The emergence of a TO animal model and a new generation of TSHR antibody assays increasingly point towards TSHR as the primary autoantigen for extrathyroidal orbital involvement. Oxidative stress in TO resulting from imbalances of the oxidation-reduction state provides a framework of understanding for smoking prevention, achieving euthyroidism and the use of antioxidants such as selenium. Progress has been made in the understanding of the pathogenesis of TO, which should advance development of novel therapies targeting cellular immunity, specifically the CD40:CD40 ligand interaction, antibody-producing B cells, cytokines, TSHR and IGF-1R and its signalling pathways. Further studies in signalling networks and molecular triggers leading to burnout of TO will further our understanding of TO. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Immunology; Inflammation; Orbit; Treatment Medical

Mesh:

Substances:

Year:  2015        PMID: 26567024     DOI: 10.1136/bjophthalmol-2015-307399

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  50 in total

1.  [Calculation of orbital fat volumes for determining treatment timing for thyroid- associated ophthalmopathy].

Authors:  Wei Jiang; Qiu-Yue Cai; Zhang-Fang Li; Zhi-Yi Chen; Yao-Sheng Luo; Shi-di Hu; Jie Shen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-05-20

Review 2.  Immunohistochemical analysis of human orbital tissue in Graves' orbitopathy.

Authors:  Y P Hai; A C H Lee; L Frommer; T Diana; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2019-09-19       Impact factor: 4.256

3.  A genome-wide DNA methylation analysis in peripheral blood from patients identifies risk loci associated with Graves' orbitopathy.

Authors:  Z Xin; L Hua; T-T Shi; X Tuo; F-Y Yang; Y Li; X Cao; J-K Yang
Journal:  J Endocrinol Invest       Date:  2017-11-30       Impact factor: 4.256

Review 4.  Thyroid eye disease: current and potential medical management.

Authors:  Jessica M Pouso-Diz; Jose M Abalo-Lojo; Francisco Gonzalez
Journal:  Int Ophthalmol       Date:  2020-01-09       Impact factor: 2.031

5.  Long-term effect of triamcinolone acetonide in the treatment of upper lid retraction with thyroid associated ophthalmopathy.

Authors:  Dong-Dong Xu; Yu Chen; Hai-Yan Xu; Hui Li; Zhu-Hua Zhang; Yu-Hua Liu
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

6.  Non-EPI-DWI for Detection, Disease Monitoring, and Clinical Decision-Making in Thyroid Eye Disease.

Authors:  C Feeney; R K Lingam; V Lee; F Rahman; S Nagendran
Journal:  AJNR Am J Neuroradiol       Date:  2020-08       Impact factor: 3.825

7.  BIOINFORMATIC ANALYSIS IDENTIFIES POTENTIALLY KEY DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS IN ORBITAL ADIPOSE TISSUES OF PATIENTS WITH THYROID EYE DISEASE.

Authors:  F F Zhu; L Z Yang
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jan-Mar       Impact factor: 0.877

8.  Novel Approaches for Immunosuppression in Graves' Hyperthyroidism and Associated Orbitopathy.

Authors:  Alan Chun Hong Lee; George J Kahaly
Journal:  Eur Thyroid J       Date:  2020-08-10

9.  Leptin receptor is a key gene involved in the immunopathogenesis of thyroid-associated ophthalmopathy.

Authors:  Ziyi Chen; Zhe Chen; Jingya Wang; Meng Zhang; Xiaofei Wang; Deji Cuomu; Bingyin Shi; Yue Wang
Journal:  J Cell Mol Med       Date:  2021-05-14       Impact factor: 5.310

10.  Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management.

Authors:  Alexander D Blandford; Dalia Zhang; Rao V Chundury; Julian D Perry
Journal:  Expert Rev Ophthalmol       Date:  2017-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.